“…In an editorial, Ponder (2011) comments on the costs of protein therapy for hemophilia B and the welcome success of gene therapy reported in the same issue of the journal. Verstraete andVandenbroucke (1955, p. 1533) state 'In the last year haemophilia has been separated into different typesnamely, the well-defined classical haemophilia A (antihaemophilic globulin deficiency) and Christmas disease or haemophilia B (Christmas factor deficiency, factor IX deficiency, plasma thromboplastin component deficiency)'. Koller (1954) cites studies, including his own, contributing to this differentiation and gives a rudimentary diagram locating types A and B separately on the X chromosome.…”